Nonalcoholic fatty liver disease and hepatic fibrosis among perinatally HIV-monoinfected Asian adolescents receiving antiretroviral therapy.
To assess and compare the prevalence of persistent hepatic abnormalities, including nonalcoholic fatty liver disease (NAFLD) and/or hepatic fibrosis, among perinatally HIV-monoinfected Asian adolescents with history of abnormal hepatic enzymes to those without, using noninvasive diagnostic tools. A...
| Main Authors: | , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Public Library of Science (PLoS)
2019-01-01
|
| Series: | PLoS ONE |
| Online Access: | https://doi.org/10.1371/journal.pone.0226375 |
| _version_ | 1819147165411311616 |
|---|---|
| author | Tavitiya Sudjaritruk Torsak Bunupuradah Linda Aurpibul Pope Kosalaraksa Nia Kurniati Jiratchaya Sophonphan Panruethai Trinavarat Pannee Visrutaratna Jiraporn Srinakarin Nataruks Chaijitraruch Thanyawee Puthanakit NAFLD Study Group |
| author_facet | Tavitiya Sudjaritruk Torsak Bunupuradah Linda Aurpibul Pope Kosalaraksa Nia Kurniati Jiratchaya Sophonphan Panruethai Trinavarat Pannee Visrutaratna Jiraporn Srinakarin Nataruks Chaijitraruch Thanyawee Puthanakit NAFLD Study Group |
| author_sort | Tavitiya Sudjaritruk |
| collection | DOAJ |
| description | To assess and compare the prevalence of persistent hepatic abnormalities, including nonalcoholic fatty liver disease (NAFLD) and/or hepatic fibrosis, among perinatally HIV-monoinfected Asian adolescents with history of abnormal hepatic enzymes to those without, using noninvasive diagnostic tools. A multicenter cohort study was conducted in Thailand and Indonesia. Adolescents aged 10-25 years who were on antiretroviral treatment (ART), had virologic suppression (HIV RNA<400 copies/mL within the past 6 months), and had no history of chronic hepatitis B/C infection were enrolled. Participants were pre-classified into 2 subgroups (1:1 ratio) as participants with history of elevated versus normal aminotransferase enzymes. NAFLD was defined as hepatic steatosis (any severity) evaluated by liver ultrasonography. Significant hepatic fibrosis was defined as liver stiffness ≥7.4 kPa evaluated by transient elastography. Participants who met the criteria for protocol-defined NAFLD and/or hepatic fibrosis were re-assessed to evaluate disease progression (persistent versus transient hepatic abnormalities) at one year later. Of 120 participants, 62 (51.7%) were male, 7 (5.8%) had central obesity, and 19 (15.8%) had insulin resistance (homeostasis model assessment of insulin resistance [HOMA-IR] >3.16). At enrollment, the median age and duration of ART (IQR) were 17.0 (14.6-19.2) years and 10.5 (7.1-12.0) years, respectively. Persistent hepatic abnormalities were identified in 5/60 participants listed in the group having history of elevated aminotransferases, corresponding to the prevalence of 8.3% (95% CI: 2.8-18.4%), whereas none (0/60) were among the group having history of normal hepatic enzymes. All 5 participants had persistent aminotransferase elevation (≥2 episodes within the past 12 months). Baseline alanine aminotransferase (ALT) >30 U/L (adjusted odds ratio [aOR]: 29.1; 95% CI: 1.7-511.8), and HOMA-IR >3.16 (aOR: 17.9; 95% CI: 1.1-289.7) were independently associated with persistent hepatic abnormalities. Among perinatally HIV-monoinfected Asian adolescents with history of elevated aminotransferase enzymes, persistent hepatic abnormalities are not uncommon. Screening for liver complications by noninvasive diagnostic tools might be considered in at risk individuals, including those with persistent ALT elevation and insulin resistance. |
| first_indexed | 2024-12-22T13:25:29Z |
| format | Article |
| id | doaj.art-dd5e774ca59044ae8ec46a8f1d963b47 |
| institution | Directory Open Access Journal |
| issn | 1932-6203 |
| language | English |
| last_indexed | 2024-12-22T13:25:29Z |
| publishDate | 2019-01-01 |
| publisher | Public Library of Science (PLoS) |
| record_format | Article |
| series | PLoS ONE |
| spelling | doaj.art-dd5e774ca59044ae8ec46a8f1d963b472022-12-21T18:24:20ZengPublic Library of Science (PLoS)PLoS ONE1932-62032019-01-011412e022637510.1371/journal.pone.0226375Nonalcoholic fatty liver disease and hepatic fibrosis among perinatally HIV-monoinfected Asian adolescents receiving antiretroviral therapy.Tavitiya SudjaritrukTorsak BunupuradahLinda AurpibulPope KosalaraksaNia KurniatiJiratchaya SophonphanPanruethai TrinavaratPannee VisrutaratnaJiraporn SrinakarinNataruks ChaijitraruchThanyawee PuthanakitNAFLD Study GroupTo assess and compare the prevalence of persistent hepatic abnormalities, including nonalcoholic fatty liver disease (NAFLD) and/or hepatic fibrosis, among perinatally HIV-monoinfected Asian adolescents with history of abnormal hepatic enzymes to those without, using noninvasive diagnostic tools. A multicenter cohort study was conducted in Thailand and Indonesia. Adolescents aged 10-25 years who were on antiretroviral treatment (ART), had virologic suppression (HIV RNA<400 copies/mL within the past 6 months), and had no history of chronic hepatitis B/C infection were enrolled. Participants were pre-classified into 2 subgroups (1:1 ratio) as participants with history of elevated versus normal aminotransferase enzymes. NAFLD was defined as hepatic steatosis (any severity) evaluated by liver ultrasonography. Significant hepatic fibrosis was defined as liver stiffness ≥7.4 kPa evaluated by transient elastography. Participants who met the criteria for protocol-defined NAFLD and/or hepatic fibrosis were re-assessed to evaluate disease progression (persistent versus transient hepatic abnormalities) at one year later. Of 120 participants, 62 (51.7%) were male, 7 (5.8%) had central obesity, and 19 (15.8%) had insulin resistance (homeostasis model assessment of insulin resistance [HOMA-IR] >3.16). At enrollment, the median age and duration of ART (IQR) were 17.0 (14.6-19.2) years and 10.5 (7.1-12.0) years, respectively. Persistent hepatic abnormalities were identified in 5/60 participants listed in the group having history of elevated aminotransferases, corresponding to the prevalence of 8.3% (95% CI: 2.8-18.4%), whereas none (0/60) were among the group having history of normal hepatic enzymes. All 5 participants had persistent aminotransferase elevation (≥2 episodes within the past 12 months). Baseline alanine aminotransferase (ALT) >30 U/L (adjusted odds ratio [aOR]: 29.1; 95% CI: 1.7-511.8), and HOMA-IR >3.16 (aOR: 17.9; 95% CI: 1.1-289.7) were independently associated with persistent hepatic abnormalities. Among perinatally HIV-monoinfected Asian adolescents with history of elevated aminotransferase enzymes, persistent hepatic abnormalities are not uncommon. Screening for liver complications by noninvasive diagnostic tools might be considered in at risk individuals, including those with persistent ALT elevation and insulin resistance.https://doi.org/10.1371/journal.pone.0226375 |
| spellingShingle | Tavitiya Sudjaritruk Torsak Bunupuradah Linda Aurpibul Pope Kosalaraksa Nia Kurniati Jiratchaya Sophonphan Panruethai Trinavarat Pannee Visrutaratna Jiraporn Srinakarin Nataruks Chaijitraruch Thanyawee Puthanakit NAFLD Study Group Nonalcoholic fatty liver disease and hepatic fibrosis among perinatally HIV-monoinfected Asian adolescents receiving antiretroviral therapy. PLoS ONE |
| title | Nonalcoholic fatty liver disease and hepatic fibrosis among perinatally HIV-monoinfected Asian adolescents receiving antiretroviral therapy. |
| title_full | Nonalcoholic fatty liver disease and hepatic fibrosis among perinatally HIV-monoinfected Asian adolescents receiving antiretroviral therapy. |
| title_fullStr | Nonalcoholic fatty liver disease and hepatic fibrosis among perinatally HIV-monoinfected Asian adolescents receiving antiretroviral therapy. |
| title_full_unstemmed | Nonalcoholic fatty liver disease and hepatic fibrosis among perinatally HIV-monoinfected Asian adolescents receiving antiretroviral therapy. |
| title_short | Nonalcoholic fatty liver disease and hepatic fibrosis among perinatally HIV-monoinfected Asian adolescents receiving antiretroviral therapy. |
| title_sort | nonalcoholic fatty liver disease and hepatic fibrosis among perinatally hiv monoinfected asian adolescents receiving antiretroviral therapy |
| url | https://doi.org/10.1371/journal.pone.0226375 |
| work_keys_str_mv | AT tavitiyasudjaritruk nonalcoholicfattyliverdiseaseandhepaticfibrosisamongperinatallyhivmonoinfectedasianadolescentsreceivingantiretroviraltherapy AT torsakbunupuradah nonalcoholicfattyliverdiseaseandhepaticfibrosisamongperinatallyhivmonoinfectedasianadolescentsreceivingantiretroviraltherapy AT lindaaurpibul nonalcoholicfattyliverdiseaseandhepaticfibrosisamongperinatallyhivmonoinfectedasianadolescentsreceivingantiretroviraltherapy AT popekosalaraksa nonalcoholicfattyliverdiseaseandhepaticfibrosisamongperinatallyhivmonoinfectedasianadolescentsreceivingantiretroviraltherapy AT niakurniati nonalcoholicfattyliverdiseaseandhepaticfibrosisamongperinatallyhivmonoinfectedasianadolescentsreceivingantiretroviraltherapy AT jiratchayasophonphan nonalcoholicfattyliverdiseaseandhepaticfibrosisamongperinatallyhivmonoinfectedasianadolescentsreceivingantiretroviraltherapy AT panruethaitrinavarat nonalcoholicfattyliverdiseaseandhepaticfibrosisamongperinatallyhivmonoinfectedasianadolescentsreceivingantiretroviraltherapy AT panneevisrutaratna nonalcoholicfattyliverdiseaseandhepaticfibrosisamongperinatallyhivmonoinfectedasianadolescentsreceivingantiretroviraltherapy AT jirapornsrinakarin nonalcoholicfattyliverdiseaseandhepaticfibrosisamongperinatallyhivmonoinfectedasianadolescentsreceivingantiretroviraltherapy AT natarukschaijitraruch nonalcoholicfattyliverdiseaseandhepaticfibrosisamongperinatallyhivmonoinfectedasianadolescentsreceivingantiretroviraltherapy AT thanyaweeputhanakit nonalcoholicfattyliverdiseaseandhepaticfibrosisamongperinatallyhivmonoinfectedasianadolescentsreceivingantiretroviraltherapy AT nafldstudygroup nonalcoholicfattyliverdiseaseandhepaticfibrosisamongperinatallyhivmonoinfectedasianadolescentsreceivingantiretroviraltherapy |